KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Randomized Phase II/III Trial Comparing Hepatectomy, Followed by mFOLFOX6 With Hepatectomy Alone for Liver Metastasis From Colorectal Cancer: Long-Term Results of JCOG0603.

Yukihide Kanemitsu, Yasuhiro Shimizu, Junki Mizusawa, Yoshitaka Inaba, Shunsuke Tsukamoto, Atsuo Takashima, Masayuki Ohue, Koji Komori, Akio Shiomi, Manabu Shiozawa, Yusuke Suwa, Takeshi Suto, Yusuke Kinugasa, Yasumasa Takii, Hiroyuki Bando, Takaya Kobatake, Masafumi Inomata, Yasuhiro Shimada, Hiroshi Katayama, Haruhiko Fukuda, JCOG Colorectal Cancer Study Group

J Clin Oncol 44(15) 1395-1400

PMID41564372
PMCIDPMC13185729
DOI10.1200/JCO-25-01231
发表日期2026-01-21
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

JCOG0603 demonstrated improved disease-free survival (DFS) with adjuvant mFOLFOX6 after hepatectomy compared with hepatectomy alone in colorectal liver-only metastasis (CRLM), but the overall survival (OS) data were immature. Here, we report OS after long-term follow-up. Eligible patients with colorectal adenocarcinoma and an unlimited number of liver metastases were randomized to adjuvant mFOLFOX6 or hepatectomy alone. DFS was the primary endpoint, and OS was a secondary endpoint. Between March 2007 and January 2019, 151 and 149 patients were randomized to adjuvant chemotherapy and hepatectomy alone, respectively. At a median follow-up of 7.7 years for disease-free surviving patients, 54 (35.8%) and 51 (34.2%) patients had died in the respective arms, (hazard ratio [HR], 1.07 [95% CI, 0.73 to 1.57]). Five-year OS was 73.4% (95% CI, 65.5 to 79.7) and 80.1% (95% CI, 72.6 to 85.7) and 7-year OS was 69.4% (95% CI, 61.2 to 76.2) and 72.4% (95% CI, 64.2 to 79.1), respectively. One patient in the adjuvant chemotherapy arm possibly died of protocol treatment-related toxicity, and one in the hepatectomy-alone arm died of post-protocol treatment complications. Five-year DFS was respectively 49.7% (95% CI, 41.5 to 57.3) and 40.5% (95% CI, 32.5 to 48.3) in the adjuvant chemotherapy and hepatectomy-alone arms (HR, 0.72 [95% CI, 0.54 to 0.97]). Long-term OS did not differ with adjuvant mFOLFOX6 compared with hepatectomy alone in resectable CRLM. Adjuvant mFOLFOX6 may delay recurrence but did not improve long-term survival.

KM 提取结果

2 个 Figure · 8 个 KM 面板

进入结果中心
KM Figure4 个面板

FIG 2.

FIG 2. Survival curves. Final OS in (A) all randomly assigned patients and (B) all eligible patients in each treatment arm. Updated DFS in (C) all randomly assigned patients and (D) all eligible patients in each treatment arm. DFS, disease-free survival; HR, hazard ratio; OS, overall survival.

A

OS

FIG 2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

OS

FIG 2. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

DFS

FIG 2. · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

DFS

FIG 2. · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure4 个面板

FIG A2.

FIG A2. Subgroup survival curves according to study phase. DFS, disease-free survival; OS, overall survival.

DFS_1st_part_phase_II

DFS

FIG A2. · Panel DFS_1st_part_phase_II

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel DFS_1st_part_phase_II 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台
查看结果
DFS_2nd_part_phase_II_phase_III

DFS

FIG A2. · Panel DFS_2nd_part_phase_II_phase_III

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel DFS_2nd_part_phase_II_phase_III 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
OS_1st_part_phase_II

OS

FIG A2. · Panel OS_1st_part_phase_II

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel OS_1st_part_phase_II 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
OS_2nd_part_phase_II_phase_III

OS

FIG A2. · Panel OS_2nd_part_phase_II_phase_III

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel OS_2nd_part_phase_II_phase_III 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. CONSORT diagram. AE, adverse event.
非 KM Figure
FIG A1.FIG A1. Subgroup analyses of DFS and OS. (A) DFS. (B) OS. DFS, disease-free survival; HR, hazard ratio; OS, overall survival.
非 KM Figure